Fortrea Holdings Inc. Common Stock Q1 2026 Earnings Recap

FTRE Q1 2026 May 6, 2026

Get alerts when FTRE reports next quarter

Fortrea’s shares rallied 27.7% following the quarter as improving commercial traction, diversification into biotech, and operational milestones notably exceeded investor expectations.

Earnings Per Share Beat

$0.16 vs $0.03 est.

+433.3% surprise

Revenue Beat

636500000 vs 628505200 est.

+1.3% surprise

Market Reaction

1-Day -0.45%

5-Day -7.48%

30-Day +5.95%

See FTRE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved a Q1 book-to-bill ratio of 1.15x, marking the third consecutive quarter above 1.1x and signaling strong commercial execution.
Biotech segment saw significant year-over-year authorization growth, driven by new client wins and increased RFP activity from early-stage and innovative therapeutic companies.
Strong double-digit pipeline growth and strategic client wins in China complement a diversified global footprint with over 1,000 employees in the region.
Launched Fortrea Intelligent Technology (FIT), an AI-powered workflow automation suite, receiving immediate positive market and customer feedback, enhancing operational differentiation.
Clinical pharmacology unit delivered its first-in-human dosing for a rare blood disorder, underscoring capability expansion beyond standard trials.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit FTRE on AllInvestView.